ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin

被引：108
|
作者：
Tomlinson, B. [1 ]
Hu, M. [1 ]
Lee, V. W. Y. [2 ]
Lui, S. S. H. [1 ]
Chu, T. T. W. [1 ]
Poon, E. W. M. [1 ]
Ko, G. T. C. [1 ,3 ]
Baum, L. [2 ]
Tam, L. S. [1 ]
Li, E. K. [1 ]
机构：
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Sch Pharm, Shatin, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Hong Kong Inst Diabet & Obes, Shatin, Hong Kong, Peoples R China
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 87卷 / 05期
关键词：
COA REDUCTASE INHIBITORS; PHARMACOKINETICS; BCRP; PHARMACOGENETICS; ATORVASTATIN; TRANSPORTER; EXPRESSION; VARIANTS; GENOTYPE; OATP1B1;
D O I：
10.1038/clpt.2009.232
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The ATP-binding cassette G2 (ABCG2) c.421C>A (rs2231142) polymorphism influences the pharmacokinetics of rosuvastatin. We examined whether this polymorphism influences the low-density lipoprotein cholesterol (LDL-C)lowering efficacy of the drug. In 305 Chinese patients with hypercholesterolemia who were treated with rosuvastatin at a dosage of 10 mg daily, the c.421A variant was found to be significantly associated with greater reduction in LDL-C level, in a gene-dose-dependent manner. As compared with subjects with the c.421CC genotype, those with the c.421AA genotype showed a 6.9% greater reduction in LDL-C level, which would be equivalent to the effect obtained by doubling the dose of rosuvastatin.
引用
收藏
页码：558 / 562
页数：5
相关论文
共 50 条
  • [1] Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol
    McLean, Cheynne C.
    Teft, Wendy A.
    Morse, Bridget L.
    Gryn, Steven E.
    Hegele, Robert A.
    Kim, Richard B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (03) : 525 - 533
  • [2] ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
    Keskitalo, J. E.
    Zolk, O.
    Fromm, M. F.
    Kurkinen, K. J.
    Neuvonen, P. J.
    Niemi, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (02) : 197 - 203
  • [3] Effects of Rosuvastatin on Low-Density Lipoprotein Cholesterol and Plasma Lipids in Asian Patients with Hypercholesterolemia
    Tan, Arthur T. H.
    Low, Lip-Ping
    Lim, Chin Hock
    Tan, Chee Eng
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2009, 16 (04) : 509 - 516
  • [4] Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol
    Kasten, Anne
    Cascorbi, Ingolf
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (06) : 519 - 528
  • [5] Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER
    Karlson, Bjorn W.
    Wiklund, Olov
    Palmer, Michael K.
    Nicholls, Stephen J.
    Lundman, Pia
    Barter, Philip J.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2016, 2 (04) : 212 - 217
  • [6] Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment
    Smit, Roelof A. J.
    Postmus, Iris
    Trompet, Stella
    Barnes, Michael R.
    Warren, Helen
    Arsenault, Benoit J.
    Chasman, Daniel I.
    Cupples, L. Adrienne
    Hitman, Graham A.
    Krauss, Ronald M.
    Li, Xiaohui
    Psaty, Bruce M.
    Stein, Charles M.
    Rotter, Jerome I.
    Jukema, J. Wouter
    PHARMACOGENOMICS, 2016, 17 (15) : 1621 - 1628
  • [7] Predictive Value of the Low-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio for the Prevention of Stroke Recurrence in Japanese Patients Treated with Rosuvastatin
    Igase, Michiya
    Kohara, Katsuhiko
    Katagi, Ryosuke
    Yamashita, Shiro
    Fujisawa, Mutsuo
    Miki, Tetsuro
    CLINICAL DRUG INVESTIGATION, 2012, 32 (08) : 513 - 521
  • [8] The Association between ABCG2 421C>A (rs2231142) Polymorphism and Rosuvastatin Pharmacokinetics: A Systematic Review and Meta-Analysis
    Song, Yubin
    Lim, Hee-Hyun
    Yee, Jeong
    Yoon, Ha-Young
    Gwak, Hye-Sun
    PHARMACEUTICS, 2022, 14 (03)
  • [9] PTPN1 polymorphisms are associated with total and low-density lipoprotein cholesterol
    Bauer, Florianne
    Charlotte, Onland-Moret N.
    Niehoff, Anne G.
    Elbers, Clara C.
    Grobbee, Diederick E.
    Wijmenga, Cisca
    van der Schouw, Yvonne T.
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2010, 17 (01): : 28 - 34
  • [10] Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid
    Ballantyne, Christie M.
    Bays, Harold E.
    Louie, Michael J.
    Smart, Jeremy
    Zhang, Yang
    Ray, Kausik K.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (15):
12345